FRAMINGHAM, Mass., March 14, 2016 /PRNewswire/ -- HeartWare
International, Inc. (NASDAQ: HTWR), a leading innovator of
less-invasive, miniaturized circulatory support technologies that
are revolutionizing the treatment of advanced heart failure, today
announced the appointment of Chadwick M.
Cornell to its Board of Directors. Mr. Cornell is a
Managing Director at Goldner Hawn Johnson & Morrison, Inc., a
middle-market private equity firm, which he joined in 2013
following his tenure as Vice President of Corporate Development at
Medtronic, Inc.
"Chad joins our Board at an
important time as we move forward to take advantage of the
significant opportunities within our ventricular assist device
portfolio and establish a strong foundation for growth," said
Doug Godshall, President and Chief
Executive Officer of HeartWare. "We expect that Chad's collective experience will provide a
relevant and insightful perspective to our Board of Directors, and
we are looking forward to his contributions to take the company to
the next level."
While at Medtronic, Mr. Cornell supported the transaction
activity of various Medtronic businesses and initiatives, and he
led the corporate development group during his last five years at
the company. As Vice President of Corporate Development, he
was responsible for global acquisition, divestiture, venture
investment and strategic transaction activity. Earlier in his
tenure with Medtronic, Mr. Cornell led transaction activity related
to interventional cardiology and cardiac surgery, as well as
musculoskeletal and international business development. Prior
to joining Medtronic, Mr. Cornell was a corporate lawyer at Sidley
Austin, LLP in Chicago,
concentrating on mergers and acquisitions and securities offerings.
Mr. Cornell earned a bachelor's degree in accounting from
Marquette University and holds a Juris
Doctorate from the University of
Pennsylvania Law School. He is a Chartered Financial
Analyst and Certified Public Accountant.
"I am eager to be joining HeartWare's Board at this time in the
company's evolution," said Mr. Cornell. "As one of two
prominent companies developing and commercializing left ventricular
assist devices for this very sick segment of the population around
the world, HeartWare has a tremendous opportunity to establish a
new level of leadership through its ongoing innovation with the
HVAD® System and the significant potential for market
expansion represented by its pipeline of next-generation
assets. I am looking forward to collaborating with the Board
of Directors and executive leadership to help propel HeartWare to
its next stage of growth."
Mr. Cornell was jointly selected as an independent director to
HeartWare's Board of Directors by HeartWare and Engaged Capital,
LLC as part of a Cooperation Agreement between the two companies
that was announced in January 2016. Mr. Cornell's appointment
expands HeartWare's Board of Directors to ten directors.
About HeartWare International
HeartWare International
develops and manufactures miniaturized implantable heart pumps, or
ventricular assist devices, to treat patients suffering from
advanced heart failure. The HeartWare® Ventricular
Assist System features the HVAD® pump, a small
full-support circulatory assist device designed to be implanted
next to the heart, avoiding the abdominal surgery generally
required to implant competing devices. The HeartWare System is
approved in the United States for
the intended use as a bridge to cardiac transplantation in patients
who are at risk of death from refractory end-stage left ventricular
heart failure, has received CE Marking in the European Union and
has been used to treat patients in 47 countries. The device is also
currently the subject of a U.S. clinical trial for destination
therapy. For additional information, please visit
www.heartware.com.
HeartWare International, Inc. is a member of the Russell
2000®, and its securities are publicly traded on The
NASDAQ Stock Market.
Forward-Looking Statements
This announcement contains forward-looking statements that are
based on management's beliefs, assumptions and expectations and on
information currently available to management. All statements that
address operating performance, events or developments that we
expect or anticipate will occur in the future are forward-looking
statements, including without limitation opportunities within our
ventricular assist portfolio, foundation for growth and market
expansion, and innovation with the HVAD System. Management believes
that these forward-looking statements are reasonable as and when
made. However, you should not place undue reliance on
forward-looking statements because they speak only as of the date
when made. HeartWare does not assume any obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
may be required by federal securities laws and the rules and
regulations of the Securities and Exchange Commission. HeartWare
may not actually achieve the plans, projections or expectations
disclosed in forward-looking statements, and actual results,
developments or events could differ materially from those disclosed
in the forward-looking statements. Forward-looking statements are
subject to a number of risks and uncertainties, including without
limitation those described in Part I, Item 1A. "Risk Factors" in
HeartWare's Annual Report on Form 10-K filed with the Securities
and Exchange Commission. HeartWare may update risk factors from
time to time in Part II, Item 1A. "Risk Factors" in Quarterly
Reports on Form 10-Q, Current Reports on Form 8-K, or other filings
with the Securities and Exchange Commission.
HEARTWARE, HVAD, MVAD, PAL, SYNERGY, CIRCULITE and HeartWare
logos are trademarks of HeartWare, Inc. or its
affiliates.
For additional information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartware.com
Phone: +1 508 739 0864
Logo - http://photos.prnewswire.com/prnh/20150901/262901LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/heartware-appoints-chadwick-m-cornell-to-board-of-directors-300235080.html
SOURCE HeartWare International, Inc.